Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases Corbus diversifies pipeline with two new mAbs that target integrins that inhibit activation of TGFβ High potency anti-αvβ8 mAb licensed from University of California San Francisco and...